Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc9e2621c2adaf7e72b3047aeb09215dd> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc9e2621c2adaf7e72b3047aeb09215dd NCIT_P378 "NCI" @default.
- Bc9e2621c2adaf7e72b3047aeb09215dd type Axiom @default.
- Bc9e2621c2adaf7e72b3047aeb09215dd annotatedProperty IAO_0000115 @default.
- Bc9e2621c2adaf7e72b3047aeb09215dd annotatedSource NCIT_C94219 @default.
- Bc9e2621c2adaf7e72b3047aeb09215dd annotatedTarget "A tetravalent bispecific antibody directed against human CD30 and the human low affinity IgG Fc region receptor (FCGR3A; CD16A), with potential immunomodulating and antineoplastic activities. Upon administration, acimtamig binds to the CD16A expressed on natural killer (NK) cells with two of its binding sites and to CD30 on CD30-expressing tumor cells with the other two binding sites, thereby selectively cross-linking tumor and NK cells. This may result in NK cell activation, antibody-dependent cellular cytotoxicity (ADCC) and eventually tumor cell lysis. CD30, a cell surface receptor and a member of the tumor necrosis factor (TNF) receptor superfamily, is overexpressed in hematologic malignancies; CD16A is specifically expressed on the surface of NK cells." @default.